Background: People who are obese often get a type of heart failure called heart failure with preserved ejection fraction. Doctors are testing a drug called tirzepatide to see if it helps people with heart failure with preserved ejection fraction and obesity.
Methods: This study gave people with heart failure with preserved ejection fraction and obesity either tirzepatide or a placebo (a fake treatment) once a week under the skin. The researchers watched the participants for about two years. They checked for bad events like heart-related hospital visits or death, and they measured things like walking distance, symptoms, weight, blood pressure, and side effects.
Results: People who took tirzepatide lost more weight than those who took the placebo. They also had fewer heart-related hospital visits and events. People on tirzepatide could walk farther and had fewer symptoms of heart failure. Blood pressure and some lab tests got better too. The drug caused more side effects like stomach upset and low blood sugar in people with diabetes, but serious side effects were similar between the two groups.
Conclusions: For people with heart failure with preserved ejection fraction and obesity, tirzepatide led to weight loss and improved heart-related outcomes, exercise ability, and symptoms over two years. It caused more mild-to-moderate side effects but did not increase serious problems. These results suggest tirzepatide may help treat heart failure with preserved ejection fraction in people who are obese.
https://pubmed.ncbi.nlm.nih.gov/39555826/